News Daiichi Sankyo launches its STING operation against cancer Daiichi Sankyo has started clinical testing of a STING agonist for cancer, a class that has been hit by safety issues and discontinued programmes.
News As Blenrep returns, GSK adds another ADC to cancer pipeline GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.
News Germany's Tubulis raises €308m for ADC pipeline Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.
News Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.
News Sutro puts lead ADC on hold, cuts staff and changes CEO Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.
News MSD starts pivotal trial of ROR1 drug in first-line lymphoma MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously untreated diffuse large B-cell lymphoma.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.